For COVID-19 vaccine updates, please review our information guide and sign up for Connect. Continue your routine care with us by scheduling an in-person appointment or Video Visit.
Myeloma Center

Bibliography

Found 3 results
[ Author(Asc)] Title Type Year
Filters: First Letter Of Last Name is G  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng W-J, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S et al..  2018.  Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.. Leuk Lymphoma. 59(6):1364-1374.
Geyer JT, Niesvizky R, Jayabalan DS, Mathew S, Subramaniyam S, Geyer AI, Orazi A, Ely SA.  2014.  IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.. Mod Pathol. 27(3):375-81.
Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ et al..  2010.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. Am J Hematol. 85(9):664-9.